Ikarian Capital, LLC Krystal Biotech, Inc. Put Options Transaction History

Ikarian Capital, LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $4 Million - $6.64 Million	-37,000 Reduced 8.98%	375,000 $66.7 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $39.5 Million - $52.7 Million	411,155 Added 48657.4%	412,000 $51.1 Million
Q3 2023 Nov 14, 2023	SELL	$108.51 - $130.22 $1.03 Million - $1.23 Million	-9,455 Reduced 91.8%	845 $98,000
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $11.3 Million - $13.1 Million	-155,600 Reduced 93.79%	10,300 $824,000
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $4.46 Million - $5.65 Million	70,700 Added 74.26%	165,900 $13.1 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $6.17 Million - $7.84 Million	95,200 New	95,200 $6.64 Million
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $11.6 Million - $25.8 Million	-292,500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $15.2 Million - $21 Million	292,500 New	292,500 $15.3 Million

309

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.06B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.